Patents by Inventor Fabian Dey

Fabian Dey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperazine compounds for the treatment of autoimmune disease
    Patent number: 11952363
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Zongxing Qiu, Wei Zhu, Ge Zou
  • DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT
    Publication number: 20240109889
    Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 4, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20240018156
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: March 6, 2023
    Publication date: January 18, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • Hetero-halo inhibitors of histone deacetylase
    Patent number: 11858939
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: January 2, 2024
    Assignee: Alkermes, Inc.
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20230416251
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: January 24, 2023
    Publication date: December 28, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • Glutarimides for medical treatment
    Patent number: 11802131
    Abstract: The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 31, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
  • Dihydrobenzimidazolones for medical treatment
    Patent number: 11787802
    Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: October 17, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
  • PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20230295109
    Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2, R3, R4 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 21, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong CHEN, Fabian DEY, Xin HONG, Xuefei TAN, Jiasu XU, Wei ZHU, Ge ZOU
  • IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20230279001
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 7, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong CHEN, Jianguo CHEN, Fabian DEY, Xin HONG, Xuefei TAN, Jiasu XU, Weixing ZHANG, Wei ZHU, Ge ZOU
  • Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
    Patent number: 11713327
    Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: August 1, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Buyu Kou, Haixia Liu, Hong Shen, Xiaoqing Wang, Weixing Zhang, Zhisen Zhang, Zhiwei Zhang, Wei Zhu
  • HYDRO-1H-PYRROLO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20230219959
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 17, 2020
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong CHEN, Fabian DEY, Dong DING, Hongtao XU, Wei ZHU, Ge ZOU
  • DIHYDROQUINOLINONES FOR MEDICAL TREATMENT
    Publication number: 20230192643
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: August 1, 2022
    Publication date: June 22, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Benzothiazole compounds for the treatment of autoimmune diseases
    Patent number: 11639352
    Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 2, 2023
    Assignee: Hoffman-La Roche Inc.
    Inventors: Wei Zhu, Ge Zou, Fabian Dey
  • Spirocyclic compounds
    Patent number: 11623929
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 11, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • Spirocyclic compounds
    Patent number: 11584748
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 21, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20230022297
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds act as antagonists of the toll-like receptors TLR7, TLR8 and/or TLR9 and are thus useful in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 26, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jianguo CHEN, Fabian DEY, Hongtao XU, Weixing ZHANG, Wei ZHU
  • TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20230015242
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 17, 2020
    Publication date: January 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian DEY, Hong SHEN, Hongtao XU, Wei ZHU, Ge ZOU
  • HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
    Publication number: 20230019060
    Abstract: The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 19, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Roger Norcross, Fabian Dey, Annick Goergler, Eric Kusznir
  • Cyclic amidine compounds for the treatment of autoimmune disease
    Patent number: 11548884
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as antagonist of TLR7 and/or TLR8 and/or TLR9 in the treatment of autoimmune diseases as well as auto-inflammation diseases.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zongxing Qiu, Hong Shen, Wei Zhu, Fabian Dey, Ge Zou, Hongtao Xu
  • HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20230002375
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 10, 2020
    Publication date: January 5, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian DEY, Dong DING, Hongtao XU, Wei ZHU, Ge ZOU